2207-27-4

Usage

Uses

Used in Chemical Synthesis:
1,2,3,4-Tetrachloro-5,5-dimethoxycyclopentadiene is used as a key intermediate in the synthesis of various organic compounds. Its unique chemical properties allow it to form endo-adducts with 1,3-cyclopentadiene, which can be further utilized in the creation of complex molecules and materials.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1,2,3,4-Tetrachloro-5,5-dimethoxycyclopentadiene is used as a building block for the development of new drugs. Its ability to form endo-adducts can be exploited to create novel molecular structures with potential therapeutic applications.
Used in Material Science:
1,2,3,4-Tetrachloro-5,5-dimethoxycyclopentadiene is used as a component in the development of advanced materials. Its chemical reactivity and ability to form endo-adducts make it a valuable asset in the creation of new polymers, plastics, and other materials with specific properties.
Used in Agrochemical Industry:
In the agrochemical industry, 1,2,3,4-Tetrachloro-5,5-dimethoxycyclopentadiene is used as a starting material for the synthesis of various pesticides and other agrochemicals. Its unique chemical properties can be harnessed to develop new compounds with improved efficacy and reduced environmental impact.
Used in Dye and Pigment Industry:
1,2,3,4-Tetrachloro-5,5-dimethoxycyclopentadiene is used as a precursor in the production of dyes and pigments. Its yellow color and chemical reactivity make it a suitable candidate for the development of new colorants with enhanced properties, such as improved stability and color intensity.

InChI:InChI=1/C7H6Cl4O2/c1-12-7(13-2)5(10)3(8)4(9)6(7)11/h1-2H3

Upstream product

• 77-47-4 hexachlorocyclopentadiene 
• 67-56-1 methanol 
• 124-41-4 sodium methylate 

Downstream Products

• 3357-59-3 3,5,5-Trimethoxy-1,2,4-trichlorocyclopentadiene 
• 40001-91-0 (+/-)-(1R,2S,4S)-1,4,5,6-tetrachloro-7,7-dimethoxybicyclo[2.2.1]hept-5-en-2-yl acetate 
• 114235-33-5 N-(p-chlorosulfonylphenyl)-3,4,5,6-tetrachloro-8,8-dimethoxybicyclo<2.2.1>hept-4-eno succinimide 
• 83448-51-5 1,2-Dibutyl-3,4,5,6-tetrachloro-benzene 
• 83448-50-4 1,2,3,4-Tetrachloro-5-pentyl-6-propyl-benzene 
• 83448-49-1 1,2,3,4-Tetrachloro-5-ethyl-6-hexyl-benzene 
• 114861-70-0 2,3,4-Trichlor-5,6-bis(trifluormethylthio)benzoesaeure-methylester 
• 114301-86-9 5,6,7,8-tetrachloro-2-methoxy-5,8-dimethoxymethano-4a,5,8,8a-tetrahydro-1,4-naphthoquinone 
• 92639-58-2 1,4,5,6-tetrachloro-7,7-dimethoxy-2-(p-bromobenzoyloxymethyl)bicyclo<2.2.1>-5-heptene 
• 78130-80-0 C₃₀H₂₆Cl₄O₃ 
• 15584-58-4 1,2,3,4-tetrachloro-7,7-dimethoxy-5-phenylbicyclo[2.2.1]hept-2-ene 
• 125455-00-7 6-tert-Butyl-3,4,5-trichlor-λ³-phosphinin-2-carbonsaeure-methylester 
• 140245-71-2 1,3,4-trichloro-5,5-dimethoxy-2-(p-methylphenoxy)cyclopentadiene 
• 135781-87-2 2,3,5-trichloro-4,4-dimethoxy-5-benzyl-2-cyclopenten-1-one 

Relevant academic research and scientific papers

(2Z)-2,3,4,5,5-Pentachloropenta-2,4-dienic acid as a minor product in the synthesis of 5,5-dimetoxytetrachlorocyclopentadiene from hexachlorocyclopentadiene

Pentachloropentadienic acid was isolated, apart from the expected 5,5-dimetoxytetrachlorocyclopentadiene, in the reaction of hexachlorocyclopentadiene with potassium hydroxide in methanol. The structure of this minor product was established by X-ray crystallography. The plausible mechanism of its formation is discussed.

INHIBITORS OF MTOR-DEPTOR INTERACTIONS AND METHODS OF USE THEREOF

Provided herein are substituted hydrazone compounds useful as inhibitors of DEPTOR. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted hydrazone compounds.

Structure-activity relationship study of small molecule inhibitors of the DEPTOR-mTOR interaction

DEPTOR is a 48 kDa protein that binds to mTOR and inhibits this kinase within mTORC1 and mTORC2 complexes. Over-expression of DEPTOR specifically occurs in the multiple myeloma (MM) tumor model and DEPTOR knockdown is cytotoxic to MM cells, suggesting it is a potential therapeutic target. Since mTORC1 paralysis protects MM cells against DEPTOR knockdown, it indicates that the protein–protein interaction between DEPTOR and mTOR is key to MM viability vs death. In a previous study, we used a yeast two-hybrid screen of a small inhibitor library to identify a compound that inhibited DEPTOR/mTOR binding in yeast. This therapeutic (compound B) also prevented DEPTOR/mTOR binding in MM cells and was selectively cytotoxic to MM cells. We now present a structure–activity relationship (SAR) study around this compound as a follow-up report of this previous work. This study has led to the discovery of five new leads – namely compounds 3g, 3k, 4d, 4e and 4g – all of which have anti-myeloma cytotoxic properties superior to compound B. Due to their targeting of DEPTOR, these compounds activate mTORC1 and selectively induce MM cell apoptosis and cell cycle arrest.

Catalytic Enantioselective Desymmetrization of Norbornenoquinones via C(sp2)-H Alkylation

The enantioselective Diels-Alder (DA) reaction with monosubstituted p-benzoquinones is an unmet challenge. A new approach for the enantioselective synthesis of monosubstituted quinone-DA adducts is presented based on C(sp2)-H alkylative desymmetrization of meso-DA adducts. Catalyzed by a tertiary amino-thiourea derivative, this reaction utilizes nitroalkanes as the alkylating agents and generates densely functionalized products bearing at least four contiguous stereogenic centers remote from the reaction site with excellent enantioselectivities.

Synthetic studies on CP-225,917 and CP-263,114: Access to advanced tetracyclic systems by intramolecular conjugate displacement and [2,3]-wittig rearrangement

An advanced intermediate related to the structures of CP-225,917 and CP-263,114 was constructed by a sequence based on the use of Grob-like fragmentation, intramolecular conjugate displacement, and [2,3]-Wittig rearrangement. A variant of the [2,3]-Wittig rearrangement was developed.